Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10654941 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Raught B, et al. (2000) Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J 19, 434-44 10654941
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S1147-p - eIF4G (human) ▲
Orthologous residues
eIF4G (human): S1147‑p, eIF4G iso1 (human): S1148‑p, eIF4G iso3 (human): S1107‑p, eIF4G (mouse): S1149‑p, eIF4G iso2 (mouse): S1135‑p, eIF4G (rat): S1147‑p, eIF4G (rabbit): S950‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
insulin increase
serum increase
LY294002 serum inhibit treatment-induced increase
wortmannin serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase

S1187-p - eIF4G (human) ▲
Orthologous residues
eIF4G (human): S1187‑p, eIF4G iso1 (human): S1188‑p, eIF4G iso3 (human): S1147‑p, eIF4G (mouse): S1189‑p, eIF4G iso2 (mouse): S1175‑p, eIF4G (rat): S1187‑p, eIF4G (rabbit): S990‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
insulin increase
serum increase
LY294002 serum inhibit treatment-induced increase
wortmannin serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase

S1231-p - eIF4G (human) ▲
Orthologous residues
eIF4G (human): S1231‑p, eIF4G iso1 (human): S1232‑p, eIF4G iso3 (human): S1191‑p, eIF4G (mouse): S1231‑p, eIF4G iso2 (mouse): S1217‑p, eIF4G (rat): S1229‑p, eIF4G (rabbit): S1034‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
insulin increase
serum increase
LY294002 serum inhibit treatment-induced increase
wortmannin serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase

S1107-p - eIF4G iso3 (human) ▲
Orthologous residues
eIF4G (human): S1147‑p, eIF4G iso1 (human): S1148‑p, eIF4G iso3 (human): S1107‑p, eIF4G (mouse): S1149‑p, eIF4G iso2 (mouse): S1135‑p, eIF4G (rat): S1147‑p, eIF4G (rabbit): S950‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
insulin increase
serum increase
LY294002 serum inhibit treatment-induced increase
wortmannin serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase

S1147-p - eIF4G iso3 (human) ▲
Orthologous residues
eIF4G (human): S1187‑p, eIF4G iso1 (human): S1188‑p, eIF4G iso3 (human): S1147‑p, eIF4G (mouse): S1189‑p, eIF4G iso2 (mouse): S1175‑p, eIF4G (rat): S1187‑p, eIF4G (rabbit): S990‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
insulin increase
serum increase
LY294002 serum inhibit treatment-induced increase
wortmannin serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase

S1191-p - eIF4G iso3 (human) ▲
Orthologous residues
eIF4G (human): S1231‑p, eIF4G iso1 (human): S1232‑p, eIF4G iso3 (human): S1191‑p, eIF4G (mouse): S1231‑p, eIF4G iso2 (mouse): S1217‑p, eIF4G (rat): S1229‑p, eIF4G (rabbit): S1034‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mass spectrometry, mutation of modification site, phosphopeptide mapping
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase
insulin increase
serum increase
LY294002 serum inhibit treatment-induced increase
wortmannin serum inhibit treatment-induced increase
rapamycin serum inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.